ClinicalTrials.gg
Active, not recruitingNCT05546931Updated Nov 19, 2026

Mobile Health Program for Rural Hypertension

An interventional study of Coaching application and WebMD in Hypertension,Essential, Adherence, Medication and Quality of Life, sponsored by University of Pittsburgh. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
334
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Essential Hypertension with a site in United States — 6 open to participants now, 11 under way, 1 of them phase 3. Essential Hypertension · United States.

Planned enrollment
19th of 46
334 · median 275
Started
2023
with 3 others
No phase
17 of 53
2 open now
Primary completion
2027-07
later than 5 of 10 live
Registered
44th of 53
by date

Among the 53 studies in Essential Hypertension with a site in United States, this one is the 19th largest by planned enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2023, is one of 17 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 44th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

6 of the 53 studies in Essential Hypertension with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Essential Hypertension studies recruiting now, 15 (35%) set no upper age limit and 20 (47%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Essential Hypertension with a site in United States, or all of them as a file.
02

Study summary

Hypertension (HTN) is the leading modifiable cause of cardiovascular disease. Rural individuals experience challenges of the rural health divide: geographic distance from providers, social isolation, limited social resources, and high rates of low health literacy. This study evaluates a home-based blood pressure monitoring (HBPM) program that provides longitudinal health education, empathic guidance, monitoring, and adaptable patient-centered coaching to rural individuals. Participants in this study will be randomized to receive (1) HBPM with the intervention; or (2) the control, consisting of HBPM and a smartphone with a general health application (WebMD).

Read the detailed description

Hypertension (HTN) has increasing prevalence, is the leading cause of cardiovascular morbidity and mortality, and contributes significantly to health care utilization and costs. Social determinants of health (SDOH) exacerbate patients' access to therapies, adherence, and health outcomes. A robust literature demonstrates the effects of income, education, health literacy, and social resources on access to HTN treatment; medication adherence; and short- and long-term likelihood of clinical adversity. In the U.S., geographic obstacles to care further complicate HTN treatment and outcomes for rural individuals. This single-center, parallel group randomized clinical trial (RCT) evaluates a home-based blood pressure monitoring (HBPM) and cardiovascular mobile health platform in rural individuals with hypertension (HTN). The intervention uses a virtual coaching platform to provide health education, monitoring, guidance, and adaptable patient-centered coaching to rural individuals. The 6-month intervention provides a personalized curriculum to promote HBPM; medication adherence; HTN education; non-pharmacologic strategies for HTN management; preparation for the clinical encounter; and enhanced problem-solving and engagement for rural individuals. The trial is 12-month duration with visits at baseline, 6, and 12 months. Individuals with poorly controlled HTN (systolic BP 140-199 or diastolic BP 90-119 mm Hg at 2 ambulatory visits) will be randomized to: (1) intervention, the HBPM coaching intervention and HBPM; or (2) control, smartphone with a general health application (WebMD) and HBPM. For both intervention and control, summaries of BP measures are provided to clinicians in order to improve HTN management for rural patients. The primary study outcome is improvement in BP from baseline to 6 months. The secondary study outcomes are comparison of adherence to antihypertensive medications and patient-reported outcomes in the intervention and usual care arms at 6 and 12 months.

03

Conditions studied

  • Hypertension,Essential
  • Adherence, Medication
  • Quality of Life

Keywords

  • hypertension
  • adherence
  • rurality
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. History of uncontrolled hypertension, identified from the electronic health record problem list and an average systolic BP 140-199 or diastolic BP 90-119 mm Hg at 2 ambulatory visits, one of which is within 6 months of study entry
  2. Residence in one of 48 counties categorized as rural by the Center for Rural Pennsylvania;
  3. English-speaking at level appropriate for and study participation;
  4. No plans to relocate from the area within 12 months of enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Heart failure necessitating hospital admission ≤3 months prior to study inclusion;
  2. Acute coronary syndrome (defined as at least 2 of the following: chest pain, ischemic electrocardiographic changes, or troponin ≥0.1 ng/mL) ≤3 months prior to study inclusion;
  3. Planned major surgery, cardiovascular or non-cardiovascular;
  4. Pregnancy or planned pregnancy within 12 months;
  5. Presence of non-cardiovascular conditions likely to be fatal within 12 months (e.g., cancer);
  6. Inability to comprehend the study protocol, defined by failing 3 times to answer correctly a set of questions during consent;
  7. Institutionalized status (e.g., nursing home, incarceration);
  8. Inability to operate a smartphone or HBPM device due to sensory or neurocognitive deficit.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
334 participants (estimated)

Study arms

  • Experimental
    Intervention

    A smartphone-based, interactive coaching application designed to enhance adherence to home-based blood pressure monitoring, provided guidance on blood pressure management, patient-facing education, and assistance with modifying behaviors associated with poor blood pressure control; connected to a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform. All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.

    Behavioral: Coaching application · Behavioral: Home-based blood pressure monitoring

  • Active comparator
    Enhanced usual care

    WebMD, a smartphone-based tool for learning about blood pressure and other health conditions. Enhanced usual care participants receive a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform. All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.

    Other: WebMD · Behavioral: Home-based blood pressure monitoring

Interventions

  • BehavioralCoaching application

    A digital application for providing education and support for home-based blood pressure monitoring.

  • OtherWebMD

    Smartphone-based application for health education and/or monitoring.

  • BehavioralHome-based blood pressure monitoring

    Device for measuring blood pressure at home with blue tooth connectivity for automated collection.

06

What researchers measure

Primary outcomes

  1. Change in systolic and diastolic blood pressure from baseline to 6 months

    Change in home-based systolic and diastolic blood pressure from baseline to 6 months between the intervention and usual care arms.

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Adherence to antihypertensive medications

    Adherence to antihypertensive medication from baseline to 6 months between the intervention and usual care arms using Proportion of Days Covered, ranging from 0 to 100%, where higher values indicate superior medication adherence.

    Time frame: Baseline, 6 months

  2. Adherence to antihypertensive medications

    Adherence to antihypertensive medication from baseline to 12 months between the intervention and usual care arms using Proportion of Days Covered, ranging from 0 to 100%, where higher values indicate superior medication adherence.

    Time frame: Baseline, 12 months

  3. Patient-Reported Outcomes

    Patient-reported outcomes between the intervention and usual care arms at 6 months measured with the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) with distinct assessments of the following: (1) physical function, (2) anxiety, (3) depression, (4) fatigue, (5) sleep, (6) ability to participate in social roles, (7) social role satisfaction, and (8) interference in functioning by pain. Each domain is scored separately, such that scores for each domain range from 4 (lowest score) to 20 (highest score), where higher scores indicate greater impairment.

    Time frame: Baseline, 6 months

  4. Patient-Reported Outcomes

    Patient-reported outcomes between the intervention and usual care arms at 12 months measured with the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) with distinct assessments of the following: (1) physical function, (2) anxiety, (3) depression, (4) fatigue, (5) sleep, (6) ability to participate in social roles, (7) social role satisfaction, and (8) interference in functioning by pain. Each domain is scored separately, such that scores for each domain range from 4 (lowest score) to 20 (highest score), where higher scores indicate greater impairment.

    Time frame: Baseline, 12 months

  5. Self-efficacy for managing medications and treatment

    Patient-reported outcomes between the intervention and usual care arms at 6 months measured with the Patient-Reported Outcomes Measurement Information System Self-efficacy for managing medications and treatment, a 10-item instrument, scored from 10 (minimum) to 40 (maximum), where higher scores indicate superior self-efficacy.

    Time frame: Baseline, 6 months

  6. Self-efficacy or managing medications and treatment

    Patient-reported outcomes between the intervention and usual care arms at 12 months measured with the Patient-Reported Outcomes Measurement Information System Self-efficacy for managing medications and treatment, a 10-item instrument, scored from 10 (minimum) to 40 (maximum), where higher scores indicate superior self-efficacy.

    Time frame: Baseline, 12 months

  7. Adherence to home blood pressure monitoring

    Quantification of home blood pressure monitoring during the 6-month intervention phase, characterized as both a continuous and categorical measure, compared by study arm.

    Time frame: From enrollment to the end of the intervention phase at 6 months.

Other outcomes

  1. Change in systolic and diastolic blood pressure from baseline to 6 months, stratified by home-supervised blood pressure at baseline visit.

    Change in home-based systolic and diastolic blood pressure from baseline to 6 months between the intervention and usual care arms, stratified by home-supervised blood pressure at baseline visit (systolic BP \<130 or \>=130 mm Hg; diastolic BP \<85 or \>=85 mm Hg in separate analyses).

    Time frame: Baseline, 6 months

07

Study locations

1 site
08

References and documents

Publications

  • Odo CC, Mrkva A, Shepherd E, Davis N, Kaleida B, Muldoon MF, Magnani JW. Effect of Health Literacy on use of a Virtual Coach to Promote Home Blood Pressure Monitoring. J Clin Hypertens (Greenwich). 2026 Jun;28(6):e70320. doi: 10.1111/jch.70320. PubMed 42324623 ↗

Individual participant data

Plan to share: Yes — The study team will share all of the individual participant data collected during the trial, after deidentification.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: The data will be available 12 months following publication of the primary results of this trial.

Access criteria: Researchers who provide a methodologically sound proposal. Proposals should be directed to the Principal Investigator at magnanij@pittt.edu. To gain access, data requestors will need to sign a data access agreement. Data will be provided directly by the study investigators. Costs associated with producing datasets and analysis will be the responsibility of investigators seeking the data.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jul 2027, 46 months after the start.

Of 70 non-industry interventional studies with no phase under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 47. This study's planned 46 months is above that.

Counting every sponsor, half of 80 studies reached it within 20 months; a quarter within 8 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Dec 2026 → Jul 2027 and completion Jun 2027 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2022
First posted
Sep 21, 2022
StartActual
Sep 4, 2023
Primary completionEst.
Jul 15, 2027was Dec 2026
CompletionEst.
Nov 15, 2027was Jun 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 19, 2026
Primary completion
Dec 2026→Jul 15, 2027
Nov 19, 2026
Study completion
Jun 2027→Nov 15, 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 2026→Jul 15, 2027
    Study completion Jun 2027→Nov 15, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05546931
Responsible party
Jared W Magnani, MD, MSc (Associate Professor, University of Pittsburgh) — Principal investigator
First posted
Sep 21, 2022
Start date
Sep 4, 2023
Primary completion
Jul 15, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion